Both patients managed their illness at home, isolated but not hospitalized.
En el umbral de septiembre de 2023, Perú confirmó la presencia de una nueva variante del COVID-19 —la EG.5, llamada Eris— en dos residentes de Lima que, gracias a su historial de vacunación, atraviesan la enfermedad con síntomas leves desde sus hogares. Este hallazgo, producto de la vigilancia molecular rutinaria, recuerda que la pandemia no ha concluido, sino que continúa su lenta transformación. Las autoridades sanitarias responden con lo que ya conocen: la vacuna, el cuidado colectivo y la atención sostenida como escudos frente a lo incierto.
- Por primera vez, la variante EG.5 circula de forma confirmada en suelo peruano, detectada mediante secuenciación molecular en dos muestras de Lima.
- Ambos pacientes —un hombre de 57 años y una mujer de 56, residentes de La Molina— presentan síntomas leves y permanecen en aislamiento domiciliario sin necesidad de hospitalización.
- El hecho de que los dos casos cuenten con tres dosis de vacuna plantea una señal alentadora: la inmunización previa parece haber amortiguado la gravedad de la infección.
- El origen del contagio permanece sin esclarecer, pues no se cuenta con información sobre viajes recientes, lo que sugiere que la variante podría estar circulando ya dentro del país.
- El Ministerio de Salud reactivó sus recomendaciones preventivas —vacunación, lavado de manos, uso de mascarilla ante síntomas— como señal de que la llegada de EG.5 merece atención institucional sostenida.
El 1 de septiembre de 2023, el Ministerio de Salud del Perú anunció la detección de los primeros dos casos de la variante EG.5 del COVID-19 en el país. Los casos fueron identificados a través de secuenciación molecular de muestras tomadas en Lima, un proceso de vigilancia rutinaria que esta vez reveló algo nuevo.
Los afectados son un hombre de 57 años y una mujer de 56, ambos vecinos del distrito de La Molina. Ninguno requirió hospitalización: los dos se recuperan en casa, con síntomas leves que no exigieron atención clínica intensiva. Ambos contaban con tres dosis de vacuna contra el COVID-19, un antecedente que las autoridades consideran relevante para explicar la benignidad del cuadro. No se dispone de información sobre viajes recientes, por lo que no es posible determinar si el contagio ocurrió dentro del país o provino del exterior.
Ante la confirmación de estos casos, el ministerio emitió un llamado a reforzar la vacunación y recordó a la ciudadanía las medidas preventivas básicas: higiene de manos, etiqueta respiratoria y uso de mascarilla ante síntomas. Aunque la variante EG.5 ya circulaba en otras regiones del mundo antes de llegar a Perú, su presencia local confirma que el virus sigue evolucionando dentro de la población peruana. Las semanas próximas dirán con qué velocidad se propaga y si la protección vacunal continúa siendo suficiente.
Peru's Health Ministry announced the detection of two cases of the EG.5 COVID-19 variant—also known as Eris—on September 1st, 2023, marking the first confirmed presence of this strain in the country. The cases were identified through molecular sequencing of two test samples, a routine procedure that had flagged something new circulating in Lima.
The two patients are a 57-year-old man and a 56-year-old woman, both residents of the La Molina district. What stands out about these cases is their mildness: neither person required hospitalization. Both are managing their illness at home, isolated from others while they recover. The symptoms they experienced were light enough that they could be monitored outside a hospital setting—a detail that matters when assessing how severe a new variant might be.
Both patients had received three doses of COVID-19 vaccine, according to the records attached to their test results. This vaccination history is significant. It suggests that even as new variants emerge and spread, the prior immunization these individuals received may have shaped how their bodies responded to infection, keeping the disease from becoming severe. The ministry's records did not include information about whether either person had traveled recently, so the source of their infection remains unclear—whether they caught it locally or brought it back from elsewhere.
In response to the detection, Peru's Health Ministry issued guidance to the public, urging people to seek vaccination or booster doses at clinics throughout the country. The ministry also reminded Peruvians of basic protective measures: washing hands regularly, covering the mouth when coughing, and wearing a mask if experiencing symptoms. These recommendations are standard public health practice, but their reissue signals that officials are treating the arrival of EG.5 as something worth taking seriously, even if these first two cases are mild.
The EG.5 variant had already been circulating in other parts of the world before reaching Peru, so the country's health authorities were not entirely unprepared. Still, the confirmation of local cases means the virus is now spreading within Peru's population, not just arriving from abroad. How quickly it spreads, whether it causes more severe illness in certain groups, and whether vaccination continues to offer protection are questions that will shape the public health response in the coming weeks.
Citas Notables
The Health Ministry urged the population to attend vaccination centers throughout Peru and reinforce preventive measures including handwashing, respiratory etiquette, and mask use when symptomatic.— Peru's Health Ministry statement
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that these two cases are mild? Couldn't a variant be dangerous even if these particular patients got lucky?
True—two mild cases don't prove the variant is harmless overall. But they do tell us something: the vaccination these people had seems to have worked. If EG.5 were causing severe illness across the board, we'd expect to see hospitalizations. The mildness is a signal worth paying attention to.
Both patients were vaccinated with three doses. Does that mean the vaccine is still working against this new variant?
It suggests it, yes. We can't say for certain from two cases, but the fact that both had prior vaccination and both stayed out of the hospital points toward some protection. That's why the ministry is pushing people to get vaccinated or boosted—they're betting on that protection holding.
The records don't say where these people caught the virus. Does that mean it's spreading silently in Lima?
It could mean that, or it could just mean the contact tracing information wasn't captured in the test paperwork. But you're right to wonder. If we don't know how they got infected, it suggests the virus is already circulating enough that people can catch it without obvious exposure.
What happens next? Is Peru going to lock down again?
Nothing in the ministry's statement suggests that. They're asking people to vaccinate and follow basic hygiene—handwashing, masking if sick. That's a measured response, not an alarm. They're watching, but they're not panicking. Yet.
Why announce this at all if the cases are mild and contained?
Transparency, partly. But also because variants matter for public health planning. If EG.5 takes hold in Peru, knowing it's here early gives the health system time to prepare, to track it, to understand how it behaves in the local population. It's early warning.